Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Skin Biology is a biotechnology company specializing in the research and development of copper-peptide based products for skin and hair rejuvenation. Founded by Dr. Loren Pickart, the discoverer of the human copper-binding peptide GHK-Cu, the company focuses on tissue remodeling, anti-aging, and regenerative medicine. Their product portfolio includes a variety of cosmeceuticals designed to stimulate collagen and elastin production while reducing inflammation and scar tissue. Skin Biology leverages decades of biochemical research to provide scientifically-backed formulations for dermatological health and wound repair. The company operates primarily through a direct-to-consumer model while maintaining a strong focus on the biological mechanisms of skin repair.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Skin Biology.